HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

benzyloxycarbonylleucyl-leucyl-leucine aldehyde

Subscribe to New Research on benzyloxycarbonylleucyl-leucyl-leucine aldehyde

proteasome inhibitor

Also Known As:

LLL cpd; MG 132; MG-132; MG132; Z-LLL; Z-Leu-Leu-Leu-al; Z-Leu-Leu-leucinal; ZLLL-CHO; ZLLLal; benzyloxycarbonyl-Leu-Leu-Leu-aldehyde; benzyloxycarbonyl-leucyl-leucyl-leucinal; carbobenzoxy-leucyl-leucyl-leucinal; carbobenzoxyl-leucinyl-leucinyl-leucinal-H; carbobenzyloxy-leucinyl-leucinyl-leucinal

Networked: 376 relevant articles (8 outcomes, 55 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Peptides: 22950
  - Oligopeptides: 168
    - Leupeptins: 1
      - benzyloxycarbonylleucyl-leucyl-leucine aldehyde: 376

Experts

1.	Park, Woo Hyun: 9 articles (04/2012 - 07/2009)
2.	Han, Yong Hwan: 6 articles (07/2010 - 07/2009)
3.	Lee, Chung Soo: 4 articles (03/2015 - 08/2004)
4.	Wang, Hua-Qin: 4 articles (01/2013 - 03/2009)
5.	Gao, Yan-Yan: 4 articles (01/2013 - 03/2009)
6.	You, Bo Ra: 4 articles (06/2011 - 07/2009)
7.	Cho, Chi Hin: 4 articles (02/2010 - 06/2008)
8.	Wu, William Ka Kei: 4 articles (02/2010 - 06/2008)
9.	Sung, Joseph Jao Yiu: 4 articles (02/2010 - 06/2008)
10.	Yu, Le: 4 articles (02/2010 - 06/2008)

Related Diseases

1.	Leukemia 01/01/2014 - "MG132 sensitizes U937 leukemia cells to DOX-induced apoptosis, increasing its anti-leukemic effectiveness." 01/01/2014 - "U937 human leukemia cells were treated with MG132, DOX, or both drugs. " 01/15/2002 - "Induction of monocytic differentiation by bryostatin1 (bryo1) conferred on THP-1 leukemia cells the ability to resist Z-LLL-CHO-induced apoptosis. " 01/01/2013 - "In this study, we investigated, in U937 human leukemia cells, the effects of PTX and the MG132 proteasome inhibitor, drugs that can disrupt the NF-κB pathway. " 01/01/2012 - "Using this protocol, we show that in human leukemia Hut-78 cells that exhibit high levels of NFκB DNA binding activity, MG132 induces nuclear translocation and accumulation of IκBα, which then specifically inhibits NFκB DNA binding. "
2.	Carcinoma (Carcinomatosis) 12/01/2008 - "After exposed to MG-132, the growth and value of (3)H-TdR incorporation of gastric carcinoma cells were obviously inhibited. " 12/01/2008 - "Our objective was to investigate mechanisms of growth inhibitory effect of MG-132 on gastric carcinoma cells. " 12/01/2008 - "However, anti-carcinoma mechanism of MG-132 is unclear. " 10/01/2004 - "Esophageal carcinoma cell strain EC9706 was treated with MG-132 to inhibit its UPP specificity. " 12/01/2008 - "Our results suggest that MG-132 inhibits telomerase activity, induces apoptosis and G(1) arrest which is associated with upregulated p27kip1 expression and downregulated survivin expression in gastric carcinoma cells."
3.	Melanoma (Melanoma, Malignant) 04/15/2011 - "In vivo studies showed that MG132 induced p53 overexpression and reduced tumor growth, suggesting an important role of p53 stabilization in controlling melanoma. " 12/29/2006 - "Studies on endogenous Spred-2 in ME4405 melanoma cells showed that pervanadate induced Spred-2 ubiquitination and a marked reduction in Spred-2 steady-state levels that was partially blocked by the proteasomal inhibitor, MG-132. " 04/01/2009 - "In this report, we examined whether ABT-737 is effective in killing melanoma cells in combination with the proteasome inhibitor MG-132, and further evaluated the mechanisms of action. " 07/01/2013 - "2-Hexyldecanol was tested in melanocyte cell culture systems (B16 mouse melanoma cells and normal human melanocytes) for its effect on proteolytic activity and melanin production, in the absence and presence of the proteasome-specific inhibitor, MG132. " 04/01/2010 - "Moreover, inhibition of melanoma cell migration by imidazole was restored by MG132, a proteasome inhibitor, via inhibition of beta-catenin degradation. "
4.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2013 - "The present study was designed to explore the therapeutic effect of Nrf2 induced by proteasomal inhibitor MG132 at a low dose (10 μg/kg) on diabetic nephropathy. " 01/01/2014 - "Diabetic rats were then randomly divided into a diabetic nephropathy group (DN group), an MG132 high concentration (MH) group, and an MG132 low concentration (ML) group. " 01/01/2013 - "Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice." 01/01/2014 - "MG132 ameliorates kidney lesions by inhibiting the degradation of Smad7 in streptozotocin-induced diabetic nephropathy." 01/01/2014 - "The proteasome inhibitor, MG132, attenuates diabetic nephropathy by inhibiting SnoN degradation in vivo and in vitro."
5.	Anoxia (Hypoxia) 10/01/2007 - "Hypoxia, in contrast to MG132, did not block the T(4)-induced D2 inactivation. " 07/01/2007 - "In contrast to BeWo cells, hypoxia produced minimal increases in GLUT1 expression in explants; however, treatment with MG-132 did upregulate syncytial basal membrane GLUT1. " 07/01/2007 - "A role for hypoxia-inducible factor (HIF)-1 was suggested by the increase in HIF-1alpha as a result of hypoxia and by the increase in GLUT1 expression following treatment of BeWo with MG-132, a proteasomal inhibitor that increases HIF-1 levels. " 07/01/2006 - "Introduction of wild-type PTEN into these cells also blunted HIF-1alpha induction in response to hypoxia and decreased HIF-1alpha accumulation in the presence of the proteasomal inhibitor MG132. " 03/01/2002 - "In papillary muscles, pretreatment with MG132 (10 microM, 90 min) was associated with enhanced recovery of the contractile parameters after a 40-min hypoxia. "

Related Drugs and Biologics

1.	Proteasome Endopeptidase Complex (Proteasome)
2.	lactacystin
3.	epoxomicin
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Cytochromes c (Cytochrome c)
6.	Streptozocin (Streptozotocin)
7.	3- (4- methylphenylsulfonyl)- 2- propenenitrile
8.	Metformin (Glucophage)
9.	ABT-737
10.	PS1145

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Aftercare (After-Treatment)
3.	Molecular Targeted Therapy
4.	Heterologous Transplantation (Xenotransplantation)
5.	Homologous Transplantation (Allograft)